Global Osteonecrosis Treatment Market - 2025-2033

The global osteonecrosis treatment market reached US$ 253.22 million in 2024 and is expected to reach US$ 403.01 million by 2033, growing at a CAGR of 5.9 % during the forecast period of 2025-2033.

Osteonecrosis, also referred to as avascular necrosis, aseptic necrosis, or ischemic bone necrosis, is a degenerative bone condition caused by the interruption of blood flow to the bone's subchondral area, leading to the death of bone cells. This condition most commonly affects the epiphysis of long bones at weight-bearing joints and, in severe cases, can destroy the subchondral bone or cause the collapse of an entire joint.

The femoral head, knee, talus, and humeral head are the most frequent sites for osteonecrosis, with the hip being the most commonly affected joint. Less commonly, it can occur in other bones such as the carpus or jaw. Early detection and intervention are crucial for the effective management of osteonecrosis. This activity explores the causes and mechanisms behind the disease and the presentation and treatment options for the most commonly affected areas.

Market Dynamics: Drivers & Restraints

Rising Incidence of Osteonecrosis

The growing incidence of osteonecrosis is a significant driver for expanding the global osteonecrosis treatment market. As more individuals are diagnosed with this condition, the demand for effective treatment options increases, fueling market growth. The aging global population is a major factor contributing to the rising number of osteonecrosis cases. Older individuals are at a higher risk of developing osteonecrosis, particularly in the hip joint. According to the World Health Organization (WHO), by 2030, 1 in 6 people will be aged 60 or older, and by 2050, the number of people aged 60 and above will reach 2.1 billion.

Osteonecrosis is most common in individuals aged 60 and above, with the hip joint being the most frequently affected. Traumatic injuries, particularly from road accidents, are key contributors to the rise in osteonecrosis, especially in younger individuals. As per World Health Organization (WHO) data in December 2023, around 1.19 million people die annually due to road traffic accidents. Road traffic injuries are the leading cause of death among children and young adults aged 5 to 29 years. As the number of traumatic injuries increases, so will the number of osteonecrosis cases. This increases the demand for treatment options like joint preservation surgery, osteotomy, and arthroplasty.

Osteonecrosis most commonly affects the hip but can also occur in the humerus, knee, and talus. It is less frequently seen in the smaller bones of the wrist, like the lunate. While it can also impact the jaw, this review focuses on the more common forms seen by orthopedic surgeons. According to the National Center for Biotechnology Information (NCBI) data in August 2023, in the United States, 10% of total hip arthroplasties are performed due to avascular necrosis (AVN), typically affecting individuals aged 30 to 65.

The increasing incidence of osteonecrosis, driven by corticosteroid use, lifestyle diseases, trauma, and an aging population, is significantly impacting the global osteonecrosis treatment market. This rising burden is pushing forward innovations in both pharmacological and surgical treatments, making osteonecrosis management a growing segment within the orthopedic and regenerative medicine industries.

Adverse Side Effects Associated with Treatment

Several factors increase the risk of developing bisphosphonate-related osteonecrosis of the jaw (BRONJ), which can act as a restraint in the global osteonecrosis treatment market. According to the National Center for Biotechnology Information (NCBI) data in July 2023, dental surgeries such as tooth extractions, periodontal treatments, oral implants, and the use of dentures can heighten bone turnover and increase the risk of osteonecrosis. Conditions like cancer, chemotherapy, low hemoglobin, diabetes, renal dialysis, hypertension, hyperlipidemia, and hypercholesterolemia further elevate the risk of developing BRONJ.

Drugs such as corticosteroids, H2 blockers, antiangiogenic agents (e.g., sunitinib, bevacizumab), erythropoietin, and cyclophosphamide therapy can increase the risk of BRONJ by affecting bone metabolism and immune response. Certain genetic factors, such as polymorphisms in farnesyl pyrophosphate synthase or CYP2C8, may predispose individuals to bisphosphonate-associated osteonecrosis, particularly in patients with multiple myeloma. Age, alcohol consumption, and tobacco use can further increase the likelihood of developing osteonecrosis, complicating treatment options.

Segment Analysis

The global osteonecrosis treatment market is segmented based on type, treatment, route of administration, and region.

Treatment:

The non-steroidal anti-inflammatory drugs segment in treatment is expected to dominate the global osteonecrosis treatment market with the highest market share

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used as a first-line treatment to manage pain and inflammation associated with osteonecrosis, a condition characterized by the death of bone tissue due to reduced blood supply. NSAIDs work by inhibiting cyclooxygenase (COX) enzymes, reducing the production of prostaglandins, which are responsible for inflammation and pain. In osteonecrosis, NSAIDs are primarily prescribed to provide symptomatic relief and to manage associated conditions such as arthritis.

The increasing prevalence of osteonecrosis due to factors such as prolonged corticosteroid use, alcohol consumption, trauma, and autoimmune diseases is driving demand for NSAIDs.Due to concerns over opioid addiction, many healthcare providers prefer NSAIDs as a safer alternative for pain management.NSAIDs are available in oral, topical, and injectable forms, offering flexibility in administration for different patient needs. With an aging population prone to bone-related conditions like osteoporosis and osteonecrosis, NSAID demand is expected to grow. These factors have solidified the segment's position in the global osteonecrosis treatment market.

Geographical Analysis

North America is expected to hold a significant position in the global osteonecrosis treatment market, with the highest market share

Osteonecrosis is a significant cause of hip arthroplasties in the U.S., affecting individuals primarily between the ages of 30 and 65. Around 10% of total hip replacements are due to avascular necrosis, indicating a strong demand for treatment solutions. The increasing number of elderly individuals in North America contributes to the demand for osteonecrosis treatments. In the U.S., 17% of the population was 65 or older in 2022, and this demographic is at a higher risk of developing osteonecrosis, further driving market growth.

The development of innovative treatment options, such as ozone injections for medication-related osteonecrosis of the jaw (MRONJ), is expected to boost the market. These treatments provide effective alternatives to surgical intervention for complex cases. The market has seen several approvals for osteonecrosis-related medications. For instance, in June 2022, Strides Pharma received FDA approval for its Ibuprofen suspension. The U.S. market for this product is estimated to be approximately $41 million, and it will be produced at the company's facility in Bengaluru. Thus, the above factors are consolidating the region's position as a dominant force in the global osteonecrosis treatment market.

Competitive Landscape

The major global players in the osteonecrosis treatment market include Pfizer Inc., Haleon Group of Companies, BASF Corporation, Johnson & Johnson, Bayer AG, Sanofi, Upsher-Smith Laboratories, LLC., Merck & Co., Inc., Procter & Gamble Pharmaceuticals, Inc., Novartis AG, Eugia US, Dr. Reddy's Laboratories, and Amgen Inc. among others.

Key Developments

• In March 2023, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that it had received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global osteonecrosis treatment market report delivers a detailed analysis with 71 key tables, more than 56 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.